Organon & Co. (NYSE:OGN) shares, rose in value, with the stock price down by -0.06% to the previous day’s close as strong demand from buyers drove the stock to $17.86.
Actively observing the price movement in the last trading, the stock closed the session at $17.87. The value of beta (5-year monthly) was 0.77 whereas the PE ratio was 4.48 over 12-month period. Referring to stock’s 52-week performance, its high was $24.79, and the low was $10.84. On the whole, OGN has fluctuated by -0.61% over the past month.
With the market capitalization of Organon & Co. currently standing at about $4.57 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. The company’s Forward Dividend Ratio is 1.12, with its dividend yield at 6.27%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.06, which is expected to increase to $1.22 for fiscal year $4.32 and then to about $4.51 by fiscal year 2025. Data indicates that the EPS growth is expected to be 4.30% in 2025, while the next year’s EPS growth is forecast to be 4.40%.
Analysts have estimated the company’s revenue for the quarter at $1.57 billion, with a low estimate of $1.53 billion and a high estimate of $1.61 billion. According to the average forecast, sales growth in current quarter could jump up 1.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $6.4 billion, representing an increase of 2.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that OGN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of OGN currently trading nearly -1.88% and 1.16% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.32, while the 7-day volatility ratio is showing 2.21% which for the 30-day chart, stands at 2.48%. Furthermore, Organon & Co. (OGN)’s beta value is 0.80, and its average true range (ATR) is 0.49.
A comparison of Organon & Co. (OGN) with its peers suggests the former has fared considerably weaker in the market. OGN showed an intraday change of -0.06% in last session, and over the past year, it shrunk by -22.62%%.
Data on historical trading for Organon & Co. (NYSE:OGN) indicates that the trading volumes over the past 10 days have averaged 1.74 million and over the past 3 months, they’ve averaged 2.77 million. According to company’s latest data on outstanding shares, there are 255.63 million shares outstanding.
Nearly 0.15% of Organon & Co.’s shares belong to company insiders and institutional investors own 79.16% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.13 million shares as on Mar 15, 2024, resulting in a short ratio of 3.87. According to the data, the short interest in Organon & Co. (OGN) stood at 3.96% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 13.34 million. The stock has risen by 23.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the OGN stock heading into the next quarter.
